Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Equity (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Return on Equity for 13 consecutive years, with 0.75% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 12.0% year-over-year to 0.75%, compared with a TTM value of 0.75% through Dec 2025, up 12.0%, and an annual FY2025 reading of 0.85%, down 17.0% over the prior year.
  • Return on Equity was 0.75% for Q4 2025 at Enanta Pharmaceuticals, up from 1.14% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.16% in Q1 2021 and bottomed at 1.14% in Q3 2025.
  • Average Return on Equity over 5 years is 0.6%, with a median of 0.55% recorded in 2023.
  • Peak annual rise in Return on Equity hit 12bps in 2025, while the deepest fall reached -35bps in 2025.
  • Year by year, Return on Equity stood at 0.4% in 2021, then increased by 4bps to 0.39% in 2022, then crashed by -71bps to 0.66% in 2023, then tumbled by -31bps to 0.87% in 2024, then grew by 14bps to 0.75% in 2025.
  • Business Quant data shows Return on Equity for ENTA at 0.75% in Q4 2025, 1.14% in Q3 2025, and 1.06% in Q2 2025.